{
  "pmid": "38975903",
  "uid": "38975903",
  "title": "Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.",
  "abstract": "To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported overall survival (OS), progression-free survival (PFS), or response outcomes of patients who received a chemo(immunotherapy) Â± targeted agent standard therapy (STx) or brexucabtagene autoleucel (brexu-cel) in the post-BTKi setting. Twenty-six studies (23 observational; three trials) reporting outcomes from 2005 to 2022 were included. Using two-stage frequentist meta-analyses, the estimated median PFS/OS for patients treated with an STx was 7.6 months (95% CI: 3.9-14.6) and 9.1 months (95% CI: 7.3-11.3), respectively. The estimated objective response rate (ORR) was 45% (95% CI: 34-57%). For patients treated with brexu-cel, the estimated median PFS/OS was 14.9 months (95% CI: 10.5-21.0) and 32.1 months (95% CI: 25.2-41.2), with a pooled ORR of 89% (95% CI: 86-91%). Our findings highlight a significant unmet need for patients whose disease progresses on a covalent BTKi.",
  "authors": [
    {
      "last_name": "Wu",
      "fore_name": "James J",
      "initials": "JJ",
      "name": "James J Wu",
      "affiliations": [
        "Kite, A Gilead Company, Santa Monica, CA, USA."
      ],
      "orcid": "0000-0003-4130-4601"
    },
    {
      "last_name": "Wade",
      "fore_name": "Sally W",
      "initials": "SW",
      "name": "Sally W Wade",
      "affiliations": [
        "Wade Outcomes Research & Consulting, Salt Lake City, UT, USA."
      ]
    },
    {
      "last_name": "Itani",
      "fore_name": "Taha",
      "initials": "T",
      "name": "Taha Itani",
      "affiliations": [
        "Kite, A Gilead Company, Munich, Germany."
      ]
    },
    {
      "last_name": "Castaigne",
      "fore_name": "Jean-Gabriel",
      "initials": "JG",
      "name": "Jean-Gabriel Castaigne",
      "affiliations": [
        "Kite, A Gilead Company, Paris, France."
      ]
    },
    {
      "last_name": "Kloos",
      "fore_name": "Ioana",
      "initials": "I",
      "name": "Ioana Kloos",
      "affiliations": [
        "Kite, A Gilead Company, Paris, France."
      ]
    },
    {
      "last_name": "Peng",
      "fore_name": "Weimin",
      "initials": "W",
      "name": "Weimin Peng",
      "affiliations": [
        "Kite, A Gilead Company, Santa Monica, CA, USA."
      ]
    },
    {
      "last_name": "Kanters",
      "fore_name": "Steve",
      "initials": "S",
      "name": "Steve Kanters",
      "affiliations": [
        "RainCity Analytics, Vancouver, Canada."
      ],
      "orcid": "0000-0003-0322-5398"
    },
    {
      "last_name": "Zoratti",
      "fore_name": "Michael J",
      "initials": "MJ",
      "name": "Michael J Zoratti",
      "affiliations": [
        "RainCity Analytics, Vancouver, Canada."
      ],
      "orcid": "0000-0003-3069-1159"
    },
    {
      "last_name": "Dreyling",
      "fore_name": "Martin",
      "initials": "M",
      "name": "Martin Dreyling",
      "affiliations": [
        "LMU University Hospital of Munich, Munich, Germany."
      ]
    },
    {
      "last_name": "Shah",
      "fore_name": "Bijal",
      "initials": "B",
      "name": "Bijal Shah",
      "affiliations": [
        "Moffitt Cancer Center, Tampa, FL, USA."
      ]
    },
    {
      "last_name": "Wang",
      "fore_name": "Michael",
      "initials": "M",
      "name": "Michael Wang",
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center, Houston, TX, USA."
      ]
    }
  ],
  "journal": {
    "title": "Leukemia & lymphoma",
    "iso_abbreviation": "Leuk Lymphoma",
    "issn": "1029-2403",
    "issn_type": "Electronic",
    "volume": "65",
    "issue": "11",
    "pub_year": "2024",
    "pub_month": "Nov"
  },
  "start_page": "1609",
  "end_page": "1622",
  "pages": "1609-1622",
  "language": "eng",
  "publication_types": [
    "Systematic Review",
    "Meta-Analysis",
    "Journal Article"
  ],
  "keywords": [
    "Humans",
    "Protein Kinase Inhibitors",
    "Lymphoma, Mantle-Cell",
    "Agammaglobulinaemia Tyrosine Kinase",
    "Drug Resistance, Neoplasm",
    "Neoplasm Recurrence, Local",
    "Antineoplastic Combined Chemotherapy Protocols",
    "Treatment Outcome",
    "Tyrosine Kinase Inhibitors"
  ],
  "article_ids": {
    "pubmed": "38975903",
    "doi": "10.1080/10428194.2024.2369653"
  },
  "doi": "10.1080/10428194.2024.2369653",
  "dates": {
    "completed": "2024-11-10",
    "revised": "2024-11-10"
  },
  "chemicals": [
    "Protein Kinase Inhibitors",
    "Agammaglobulinaemia Tyrosine Kinase",
    "BTK protein, human",
    "Tyrosine Kinase Inhibitors"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "all_publications",
    "retrieved_date": "2025-07-30T15:14:08.604428",
    "pmid": "38975903"
  }
}